Product · #4 of 27 · peri/menopause
Thorne Perimenopause Complete
Capsule from Thorne, made by Thorne Research. Daily serving: 2 capsules.
Last updated · Price and ratings checked Nov 19, 2026
In short: Thorne Perimenopause Complete scores 64.6/100 in our ranking (#4 of 27). It costs $1.73 a day at the regular price. Evidence: EstroG-100 514 mg (trial dose) + hops; best ingredient grade C (EstroG-100). It is listed in NSF’s public registry.
Pros
- Listed in NSF's public registry (NSF/ANSI 173 contents certification, NSF Certified for Sport).
- Evidence: EstroG-100 514 mg (trial dose) + hops.
Cons
- Expensive: $1.73 a day at the label dose.
- Few Amazon ratings so far (72).
Flags
Liver cautionAbove EFSA limit
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| EstroG-100 botanical blend | 514 mg | EstroG-100 C |
| Hops extract (Lifenol, flower) | 85 mg | Hops (8-PN) C- |
| Vitamin B6 (pyridoxal 5'-phosphate) | 30 mg | Not in our evidence library |
Replaces Thorne Meta-Balance, which is discontinued.
Evidence
Our evidence score: 25/40, because: EstroG-100 514 mg (trial dose) + hops.
Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.
Ingredient evidence
- EstroG-100 C (514 mg here)
EstroG-100 is a Korean three-herb blend studied for occasional hot flashes and other common menopause symptoms* in three small placebo-controlled trials. The EU food-safety authority (EFSA) judged it safe only up to 175 mg a day, below the 514 mg a day used in most products. The Menopause Society 2023: Not specifically assessed (falls under 'supplements/herbal remedies – not recommended'). - Hops (8-PN) C- (85 mg here)
Hop extract, a source of the potent plant estrogen 8-prenylnaringenin (8-PN), has been studied in a few small trials for occasional hot flashes*, with mixed results. The Menopause Society 2023: Not assessed.
Studies
Studies on its ingredients (7)
-
The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study.
64 US women took EstroG-100 (a Korean 3-herb blend) or placebo for 12 weeks. Overall symptom scores, including hot flashes and vaginal dryness, improved much more than with placebo. It is one small study and has not been widely repeated.
- Who
- 64 women (US, multi-ethnic)
- Dose
- EstroG-100 daily
- Duration
- 12 weeks
- Result
- Kupperman Index 29.5→11.3 vs 29.2→23.7 placebo (P<.01); vaginal dryness improved.
- Funding
- Not stated in abstract (ingredient maker Naturalendo Tech is the developer; not verified). Funding not stated
-
Estro G-100 herbal extract and hot flashes in postmenopausal women: A randomized double-blinded controlled trial.
In Iran, postmenopausal women took EstroG-100 or placebo; only 70 of 120 were analyzed. By week 6 the EstroG-100 group reported fewer hot flashes. The high drop-out rate weakens the result.
- Who
- 120 randomized, 70 analyzed (Iran)
- Dose
- EstroG-100 daily
- Duration
- 12 weeks (results reported at weeks 3–6)
- Result
- Fewer mild, moderate and severe hot flashes vs control at week 6 (P<.001).
- Funding
- Not stated in abstract. Funding not stated
-
Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.
80 women took OLLY's EstroG-100 + GABA product or placebo for 5 weeks. Hot flashes, sleep and mood improved more than placebo. The study was run by the company that sells the product.
- Who
- 80 women
- Dose
- EstroG-100 514 mg + GABA 50 mg (OLLY Mellow Menopause)
- Duration
- 5 weeks
- Result
- Hot-flash intensity and number fell vs placebo from days 1–2; sleep, mood and sexual function improved at later time points.
- Funding
- Authors are employees of OLLY PBC, the product's manufacturer. Industry-linked
-
Statement on the safety of EstroG-100™ as a novel food pursuant to Regulation (EC) No 258/97.
Europe's food-safety agency approved EstroG-100 only up to 175 mg a day – about a third of the dose used in many US products and trials – because of limited long-term safety data.
- Who
- n/a (EU safety opinion)
- Dose
- max 175 mg/day judged safe
- Duration
- n/a
- Result
- EFSA considered EstroG-100 safe at 175 mg/day in postmenopausal women (lower than the 514 mg/day proposed) because of liver/blood findings in animal studies and limited human data.
- Funding
- EFSA (independent EU regulator). Independent / academic
-
A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts.
67 Belgian women took a hop extract or placebo for 12 weeks. There was an early benefit at 6 weeks that was no longer significant at 12 weeks.
- Who
- 67 women
- Dose
- hop extract 100 or 250 µg 8-PN/day
- Duration
- 12 weeks
- Result
- 100 µg beat placebo at 6 weeks but not 12 weeks; no dose-response.
- Funding
- Not stated in abstract. Funding not stated
-
A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts.
36 Finnish women took a hop extract and placebo for 8 weeks each. Overall it did not beat placebo.
- Who
- 36 women (crossover)
- Dose
- standardized hop extract
- Duration
- 16 weeks (8+8)
- Result
- No significant overall effect; some time-specific improvements.
- Funding
- Not stated in abstract. Funding not stated
-
The effect of Hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial.
120 Iranian women took hops or placebo for 12 weeks and reported fewer hot flashes with hops. One unreplicated study.
- Who
- 120 women (Iran)
- Dose
- hop tablets
- Duration
- 12 weeks
- Result
- Greene score and hot-flash counts lower vs placebo at weeks 4, 8, 12.
- Funding
- Academic (Tabriz Univ.). Independent / academic
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $52.00 (60 units, 30 days at label dose) |
|---|---|
| Cost per day | $1.73 |
| Subscription | $46.80 (10% off) |
| Price notes | Amazon B0GMYXQJTN $52.00 |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: no average shown from 72 ratings on Amazon (checked Nov 19, 2026)
Brand site: ★ 3.5, 25 reviews on thorne.com (checked Nov 19, 2026). Brand-site reviews are moderated by the brand.
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- NSF/ANSI 173 Contents Certified – 'Thorne® Perimenopause Complete' (info.nsf.org Thorne listing, 2026-11-19) Registry-verified
- NSF Certified for Sport – listed in nsfsport.com search 'perimenopause' (2026-11-19) Registry-verified
Claims made by the brand
- “gluten-free” Brand claim
- “dairy-free” Brand claim
- “soy-free” Brand claim
Registry check: info.nsf.org · nsfsport.com
Who's behind it
| Brand | Thorne |
|---|---|
| Owner / company | Thorne Research (Summerville, SC). Reported to have been taken private by L Catterton in 2023. Unverified |
| Founders | Not stated on the pages we read. |
| Where it's made | Not stated on the pages we read. |
| Medical advisors named | None named on the pages we read. |
| Source | thorne.com |
Flags & safety
Legal, regulatory and quality flags
- Thorne Meta-Balance (black cohosh 200 mg, chaste tree 200 mg, wild yam 200 mg, Pycnogenol 60 mg) is discontinued: thorne.com URL 404 and no Amazon listing (2026-11-19). Many review sites still recommend it.
- Contains EstroG-100 at 514 mg/day. EFSA judged EstroG-100 safe only up to 175 mg/day in postmenopausal women, because of liver and blood findings in animal studies. study
Ingredient safety notes
- EstroG-100: EFSA: safe only up to 175 mg/day in postmenopausal women (vs 514 mg/day used in many products) due to liver/haematology findings in animals and limited human data. Angelica species may interact with anticoagulants (dong quai concern noted by NAMS).
- Hops (8-PN): 8-PN is a potent phytoestrogen – caution in hormone-sensitive conditions.
Not verified
- Ownership (reported L Catterton take-private, 2023). Unverified
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.